RESUMEN
The progressive nature of type 2 diabetes mellitus leads to the need for insulin therapy in a significant proportion of patients. Very often start of insulin therapy in type 2 diabetes mellitus (T2DM) is associated with weight gain and a significant increase of hypoglycemia's risk. However, innovative options, such as fixed ratio combinations of glucagon-like peptide 1 receptor agonists (GLP-1RA) and basal insulin, minimize weight gain and hypoglycemia risks and allow a greater proportion of patients to achieve individual glycemic control goals without compromising safety parameters. This review includes a description of the randomized clinical trials, as well as the results of real clinical practice of the use of two currently existing fixed ration combinations of GLP-1RA and basal insulin - iDegLira and iGlarLixi.
Asunto(s)
Diabetes Mellitus Tipo 2 , Hipoglucemia , Humanos , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Insulina/uso terapéutico , Insulina Regular Humana , Hipoglucemia/inducido químicamente , Aumento de PesoRESUMEN
2021 marks the 100th anniversary of the discovery of insulin, an event that forever changed the lives of people with diabetes mellitus. At present patients around the world experience the miracle of insulin therapy every day. A disease that used to kill children and teenagers in 2 years in 1920 has become a disease that can be controlled with a possibility to lead a long productive life. Over the past century, the great discovery of Banting, Best and Collip has forever changed the world and saved millions of lives. This review is devoted to the history of the development of insulin and its further improvement: from the moment of discovery to the present days. Various generations of insulin are considered: from animals to modern ultrashort and basal analogues. The article ends with a brief review of current trends in the development of new delivery methods and the development of new insulin molecules. Over the past century, insulin therapy has come a long way, which has significantly improved the quality of life of our patients. But research is actively continuing, including in the field of alternative methods of insulin delivery, which are more convenient for the patient, as well as in the development of «smart¼ molecules that will have a glucose-dependent effect.
Asunto(s)
Diabetes Mellitus , Insulina , Animales , Humanos , Diabetes Mellitus/tratamiento farmacológico , Insulina/historia , Insulina/uso terapéutico , Insulina Regular Humana , Calidad de Vida , Historia del Siglo XX , Historia del Siglo XXIRESUMEN
BACKGROUND: Procurement of medicines reflects the demand and frequency of prescribing certain drugs, which makes it possible to assess the quality of medical care and compliance with standards. The Russian pharmaceutical market is dynamically developing and expanding, therefore, the commercial sector of drug circulation is a significant part of it and should be studied along with public procurement. Given the significant number of patients diagnosed with diabetes mellitus (DM) in our country, we considered it appropriate and interesting to analyze the structure and volume of turnover of antidiabetic drugs in the retail trade over five years. AIM: to assess the dynamics of the cost and sales volumes of hypoglycemic drugs in the commercial sector for 2019-2020 compared to 2016. MATERIALS AND METHODS: The analysis was made on the basis of the data of antidiabetic drugs purchases in Russian pharmacies in 2016 and 2019-2020, according to 95257 pharmacies data. RESULTS: In 2020, compared to 2016, we see a significant increase in the number of packages purchases (+14,952,897 rub.) and the purchases total amount (+9,377,975,722 rub.), in parallel with the increase in average price per box of the hypoglycemic drug +199, 57 rub. The average price for DPP4 decreased. The cost per pack of metformin remains one of the lowest, second only to glibenclamide and gliclazide. The most expensive drugs include GLP1 group representatives. Insulin purchases have halved, when budget for GLP1 have increased by 10 times, for SGLT2 by 9.5 times, and for DPP4 by 2.1 times. In 2020, metformin gliclazide, a combination of glibencladimide with metformin, glibenclamide and vildgaliptin remain leaders in the number of purchased packages. The purchase leaders in terms of budget share are: metformin, gliclazide, liraglutide, vildagliptin and dapagliflozinCONCLUSION: There are positive trends in the demand for more effective innovative hypoglycemic drugs, however, the affordability of drugs still dominates over the feasibility of their clinical use, and a high percentage of drug turnover in the commercial sector might indicates insufficient funding for drug provision for patients with diabetes mellitus.
Asunto(s)
Gliclazida , Metformina , Farmacias , Farmacia , Humanos , Hipoglucemiantes/uso terapéutico , Gliburida , Dipeptidil Peptidasa 4 , Metformina/uso terapéuticoRESUMEN
OBJECTIVE: To study the effect of Unifuzol (L-arginine sodium succinate) on cognitive impairment, cerebral blood flow, and damage to the tissues of the hippocampus and cerebral cortex during a 10-day course of administration to rats with chronic cerebral ischemia (CCI) caused by bilateral stenosis of the common carotid arteries (CCA). MATERIAL AND METHODS: The study was conducted on male rats with CCI caused by bilateral stenosis of the CCA by 60%. 40 days after surgery, rats received Unifusol (21, 42 and 84 ml/kg), nicergoline (10 mg/kg), citicoline (500 mg/kg) or placebo (0.9% NaCl) for 10 days. Next, cognitive impairments were assessed in the Morris Water Maze and the New Object Recognition (NOR) test, as well as the level of motor and exploratory activity in the Open Field test. The level of cerebral blood flow was determined immediately after the CCA stenosis and at the end of the experiment. Animals were euthanized in a CO2 incubator, after which the brain was removed and subjected to morphometric analysis. RESULTS: In animals that were modeled with CCA stenosis, pronounced behavioral and cognitive impairments occurred as a result of a decrease in blood flow in the vessels of the brain and subsequent changes in the tissues of the hippocampus and the cerebral cortex. Intravenous course administration of Unifuzol at doses of 42 and 84 ml/kg to animals with CCI was comparable in efficiency to nicergoline and citicoline, which was expressed in greater preservation of the cognitive abilities of animals in the Morris Water Maze and NOR tests. In the Open Field test, animals injected with Unifusol at doses of 42 and 84 ml/kg performed more acts of motor and exploratory activity than animals from the placebo group, and had a higher level of cerebral blood flow (compared to animals that were injected with citicoline). Based on the results of a morphological study, it was found that the most significant neuroprotective effect was provided by nicergoline and Unifuzol (at doses of 42 and 84 ml/kg). CONCLUSION: Unifuzol at a course of administration at doses of 42 and 84 ml/kg, comparable to the reference drugs nicergoline and citicoline, reduces the severity of psychoneurological deficit in animals with CCI, comparable to them improves the microcirculation of brain tissues, preventing damage to brain tissues.
Asunto(s)
Isquemia Encefálica , Estenosis Carotídea , Disfunción Cognitiva , Nicergolina , Choque , Ratas , Masculino , Animales , Constricción Patológica , Citidina Difosfato Colina/uso terapéutico , Nicergolina/uso terapéutico , Disfunción Cognitiva/etiología , Disfunción Cognitiva/complicaciones , Arteria Carótida Común , Hipocampo , Estenosis Carotídea/complicaciones , Estenosis Carotídea/tratamiento farmacológico , Estenosis Carotídea/psicología , Isquemia Encefálica/complicaciones , Isquemia Encefálica/tratamiento farmacológico , Choque/complicaciones , Modelos Animales de EnfermedadAsunto(s)
Endotelio Vascular/fisiopatología , Hormonas Esteroides Gonadales/deficiencia , Hipertensión/fisiopatología , Arteria Cerebral Media/fisiopatología , Vasodilatación/fisiología , Acetilcolina , Animales , Arginina , Modelos Animales de Enfermedad , Endotelio Vascular/diagnóstico por imagen , Endotelio Vascular/efectos de los fármacos , Femenino , Hormonas Esteroides Gonadales/sangre , Hipertensión/sangre , Hipertensión/etiología , Arteria Cerebral Media/diagnóstico por imagen , Arteria Cerebral Media/efectos de los fármacos , Nitroglicerina , Ratas , Ratas Wistar , Factores de Riesgo , Ultrasonografía Doppler Transcraneal , VasodilatadoresRESUMEN
This review discusses probable pathways in the development of endothelial dysfunction caused by the insufficiency of sex hormones and considers the possibility of its correction with the aid of estrogen.
Asunto(s)
Endotelio Vascular/metabolismo , Terapia de Reemplazo de Estrógeno/métodos , Estrógenos/uso terapéutico , Hormonas Esteroides Gonadales/deficiencia , Animales , Endotelio Vascular/fisiopatología , Femenino , Humanos , MasculinoRESUMEN
The review of literature deals with the implication of estrogen deficiency in the development of endothelial dysfunction and its related cardiovascular diseases.